Drug intelligence / Profile preview

PP 1420

Development stage: Phase 2
Lead developer: Imperial College London
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

PP 1420 is an investigational drug developed as a potential treatment for obesity. It has undergone phase 1 and phase 2 clinical trials, with the highest development phase being a terminated phase 2 trial for obesity. The mechanism of action of PP 1420 remains unknown, and it does not represent a novel mechanism. In clinical studies, subcutaneous administration of PP 1420 was well tolerated in healthy human subjects at single doses between 2-8 mg, with no serious adverse effects reported. The drug was developed by Imperial College London[1][2].

Other names: Pancreatic polypeptide 1420

Targets

NPY4R (Neuropeptide Y receptor Y4)

Beyond the preview

Go deeper on PP 1420.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP 1420.

Explore the full profile